COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Clinical Trials Condition

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

15 results for "Cancer" and "Prostate"

Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors

This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Protocol No
TRISHULA-TTX-030-002
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Prostate and Urologic Cancers, Head and Neck Cancers

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Protocol No
MERCK-MK-7339-010
Sub Category
Prostate and Urologic Cancers

A Phase 1/1b, First-In-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Oral TP-1454 Alone And In Combination With Ipilimumab And Nivolumab

The primary purpose of this research study is to determine the preliminary safety of TP-1454 alone, or TP-1454 in combination with ipilimumab and nivolumab, at different doses to find out what effects, if any, it has on people with solid tumors. This study will also gain information about the pharmacokinetics or PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body) and pharmacodynamic (PD) biomarkers (which are used to examine the drug effect on the body and/or the tumor).

Protocol No
TOLERO-TP-1454-101
Sub Category
Early Phase/Multiple Disease Site Cancers

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 Naïve and PD-(L)1 Pretreated Patient Populations with Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

Three cohorts (groups) of subjects will be enrolled into the Module A part of the study based on cancer diagnosis, previous treatment and how the cancer responded to the previous treatment that was given. In Cohort 1 patients with gastroesophageal adenocarcinoma will be tested; Cohort 2 will test patients with any type of solid tumor cancer that benefitted previously from an anti-PD-1/PD-(L)1 treatment; and Cohort 3 will test patients that did not benefit from a previous anti-PD-1/PD-(L)1 treatment. The types of solid tumor cancers to be enrolled into Cohort 3 will include: previously treated colorectal cancer, merkel cell carcinoma, and squamous cell skin carcinoma; squamous cancers of the head and neck, cervix, anus,
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
and mesothelioma.
Protocol No
BI-1381-0009-MULTI31
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.
Protocol No
NGM-18-0402
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers